Psychedelics and Psychedelic-Assisted Psychotherapy
The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Abstract
Objective: The authors provide an evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders. Methods: Searches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reporting on “psilocybin,” “lysergic acid diethylamide,” “LSD,” “ayahuasca,” “3,4-methylenedioxymethamphetamine,” and “MDMA,” in human subjects, published between 2007 and July 1, 2019. A total of 1,603 articles were identified and screened. Articles that did not contain the terms “clinical trial,” “therapy,” or “imaging” in the title or abstract were filtered out. The 161 remaining articles were reviewed by two or more authors. The authors identified 14 articles reporting on well-designed clinical trials investigating the efficacy of lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ayahuasca for the treatment of mood and anxiety disorders, trauma and stress-related disorders, and substance-related and addictive disorders as well as in end-of-life care. Results: The most significant database exists for MDMA and psilocybin, which have been designated by the U.S. Food and Drug Administration (FDA) as “breakthrough therapies” for posttraumatic stress disorder (PTSD) and treatment-resistant depression, respectively. The research on LSD and ayahuasca is observational, but available evidence suggests that these agents may have therapeutic effects in specific psychiatric disorders. Conclusions: Randomized clinical trials support the efficacy of MDMA in the treatment of PTSD and psilocybin in the treatment of depression and cancer-related anxiety. The research to support the use of LSD and ayahuasca in the treatment of psychiatric disorders is preliminary, although promising. Overall, the database is insufficient for FDA approval of any psychedelic compound for routine clinical use in psychiatric disorders at this time, but continued research on the efficacy of psychedelics for the treatment of psychiatric disorders is warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, comorbid conditions such as suicidality and substance use disorders further complicate research efforts (13, 18, 20, 21).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [21]
In the citing paper
“Ketamine has also been considered for the treatment of PTSD, although information on this matter is still lacking (Krediet et al., 2020; Reiff et al., 2020).”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · doi:10.36131/cnfioritieditore20200606 · cites this paper as Reiff et al., 2020
In the citing paper
“Psychedelics such as psilocybin and lysergic acid diethylamide (LSD) are also novel therapeutics for MDD that show promise in clinical trials [124-126].”
From Beyond the serotonin deficit hypothesis: Communicating a neuroplasticity framework of major depressive disorder (2024) · cites this paper as [126]
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Ketamine NMDA antagonist Deficits in vigilance, verbal fluency, delayed recall, and tests of frontal lobe function (121) Derealization, depersonalization (8, 120, 121, 124); illusions in all sensory domains and perceptual alterations (121) Amotivation, emotional dulling, hostility (121); anxiety (121, 123) Improved mo…”
BackgroundGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Journal of Transpersonal Psychology
(1977) · Journal of Humanistic Psychology · doi:10.1177/002216787701700308 · Cited by 1,732
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 4×
“The mean change in HAM-D score 21 days after drug administration was 211.4. a AASE=Alcohol Abstinence Self-Efficacy Scale; BDI=Beck Depression Inventory; CAPS=Clinician-Administered PTSD Scale; LSD=lysergic acid diethylamide; DMT=N,N-dimethyltryptamine; HADS=Hospital Anxiety and Depression Scale; HAM-A=Hamilton Anxiet…”
BackgroundMethodInfluentialDrug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 3×
“(23) conducted an openlabel pilot study evaluating the feasibility and efficacy of”
BackgroundCarhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Research works printed but not linked: 13
- Lee M, 1992, Acid Dreams: The Complete History of LSD: The CIA, The Sixties, and Beyond
- Darling DC, 2006, Sacred Mushroom of Visions: Teonanácatl: A Sourcebook on the Psilocybin Mushroom
- Pahnke WN, 1969, Int Psychiatry Clin, 5, 149
- Abramson HA: The Use of LSD in Psychotherapy, in Transactions of a Conference on d-Lysergic Acid Diethylamine (LSD-25). New York: Josiah Macy Jr. Foundation Publications, 1959
- Grof S, 1977, The Human Encounter With Death
- Labate BC, 2009, Ayahuasca Religions: A Comprehensive Bibliography and Critical Essays
- Holland J, 2001, Ecstasy: The Complete Guide
- Mithoefer MC, 2013, A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder
- Grof S, 2008, LSD Psychotherapy
- Kalant H, 2001, CMAJ, 165, 917
- Preller KH, 2018, Behavioral Neurobiology of Psychedelic Drugs, 221
- Aarde SM, 2017, Neuropharmacology of New Psychoactive Substances (NPS): The Science Behind the Headlines, 145
- Heifets BD, JAMA Psychiatry
Cited by
Items 501–600 of 647
Kapfhammer, H. (2022) · Springer eBooks · doi:10.1007/978-3-662-65873-4_12
The Future for Psychedelic Agents in the Treatment of Posttraumatic Stress Disorder
Haycraft, A. L. (2023) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2023.104586 · Cited by 3
Rychle působící antidepresiva -otázky a odpovědi
Ustohal, L., & Bartečková, E. (2023) · Psychiatrie pro praxi · doi:10.36290/psy.2023.005
Virgilio, V. D., Minerbi, A., Deol, J. K., Aggerwal, S., Safi, T., & Gupta, G. (2023) · medRxiv · doi:10.1101/2023.05.10.23289787
“…challenges some authors highlight overlapping symptomatology, treatments, and functional consequences, while other authors argue causative relationships where these conditions influence each other (Aronoff, 2016; Di Virgilio et al., 2023; Fornasari, 2012; Kynast et al., 2013; Rieder et al., 2017).”
BackgroundHasler, F. (2023) · transcript Verlag eBooks · doi:10.14361/9783839445716 · Cited by 3
Tetem, J., Fischmann, T., & Möller, T. J. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/ztyxh
Experiencias psicodélicas: fenomenología, potenciales terapéuticos y modelos explicativos
Chernoff, T., Kliger, B., & Venturini, D. H. (2023) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v34i160.463 · Cited by 2
Canale, L., Raval, D., Chatha, P., Penn, K., Weber, C. G., Stout, C., & Weleff, J. (2023) · American Journal of Psychiatry Residents Journal · doi:10.1176/appi.ajp-rj.2023.190103
Stufe Sechs: Zugang zu Leidenschaft und anderen inneren Ressourcen
Broder, M. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-42340-6_8
Membrane Permeation of Psychedelic CompoundsPreprint
Palmisano, V. F., Agnorelli, C., Fagiolini, A. M., Erritzøe, D., Nutt, D., Faraji, S., & Nogueira, J. J. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-wlxmw
Editorial: Psychoactive plants and fungi: biochemistry and genomics
de Haro, L. A., Berman, P., & Iriti, M. (2023) · Frontiers in Plant Science · doi:10.3389/fpls.2023.1327345
“Psychedelic-assisted therapy is reshaping mental health treatment paradigms by harnessing the potential of psychoactive substances to address conditions like depression, post-traumatic stress disorder (PTSD), and addiction (Reiff et al., 2020).”
BackgroundBrunnhuber, S. (2024) · Sustainable finance · doi:10.1007/978-3-031-48113-0_2
Breeksema, J. J. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.912040905 · Cited by 1
Masking influences: A systematic review of placebo control and blinding in psychedelic studiesPreprint
Barstowe, A., & Kajonius, P. (2024) · Research Square · doi:10.21203/rs.3.rs-3973393/v1
Neuroimaging features of psilocybin-induced toxic-metabolic encephalopathy in an adolescent
Ho, C., & Crawford, J. R. (2024) · BMJ Case Reports · doi:10.1136/bcr-2024-259721
Introduction to the EMBARK Approach
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0003
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0006
Bringing It Home and Carrying It Forward
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0009
Considerations Prior to Meeting With a Participant
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0005
INTRODUCTION: A New Approach for the Whole Person
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0001
Choosing Suggested Integration Goals
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0004
Working Within the EMBARK Domains Cheat Sheet
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0003
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0007
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0002
An Overview of Psychedelic-Assisted Therapy
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0002
Personal Care for the Therapist
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0001
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0008
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.002.0004
EMBARK Mechanisms of Change in the Treatment of Depression
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0004
Jensen, A. A., Cecchi, C. R., Hibicke, M., Bach, A. H., Kaadt, E., Märcher-Rørsted, E., Nichols, C. D., Elfving, B., & Kristensen, J. L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.19.590212
Serine 3.39 and isoleucine 4.60 are key sites for 5‐HT 2A R‐mediated G s signaling
Xie, L., Liu, X., Yao, Y., Tan, B., & Su, R. (2024) · FEBS Letters · doi:10.1002/1873-3468.14904
Fármacos enteógenos y la depresión resistente al tratamiento: Una revisión narrativa
Herrera-Solís, A., Morelos, J. C., Ruiz‐Contreras, A. E., Méndez‐Díaz, M., Ortega-Gómez, A., & Prospero-Garcia, O. E. (2024) · PSICUMEX · doi:10.36793/psicumex.v14i1.628 · Cited by 1
Hunt, K. J. (2024) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/4284 · Cited by 1
Chapter 51. Treatment of Posttraumatic Stress Disorder
Nemeroff, C. B., Rosen, V., & Ortiz, N. F. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as51
Self-citationPTSD Treatment: An Inquiry into the Promising Potential of Psilocybin
Folorunsho, I. L., Harry, N. M., Obiajunwa, C., Arubuolawe, O. O., Busari, A. K., Ibeneme, C., & Anugwom, G. (2024) · Journal of Advances in Medicine and Medical Research · doi:10.9734/jammr/2024/v36i85525
Le LSD, entre scène artistique et traitement des troubles anxio-dépressifs
Amrouche, L. (2024) · Actualités Pharmaceutiques · doi:10.1016/j.actpha.2024.06.009
Chemical Reactivity Parameters to Analyze Psychedelics: How Do We Explain the Potency of the Drugs?
Martínez, A., Caballero, A., Ramírez, R., Perez-Sanchez, E., Quevedo, E., & Salvador-García, D. (2024) · ACS Omega · doi:10.1021/acsomega.4c05726 · Cited by 2
Levin, A. W., Sarparast, A., Nagib, P. B., & Davis, A. K. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00395 · Cited by 2
Barnett, B. S. (2024) · medRxiv · doi:10.1101/2024.10.12.24315367
“The therapeutic potential of psychedelics for psychiatric and substance use disorders has generated significant scientific interest in recent decades (Reiff et al. 2020; Singh 2023; Spencer, Miniño, and Warner 2022).”
BackgroundFernandes-Nascimento, M. H., Viana-Ferreira, K., Assad, E. N., & Negrão, A. B. (2024) · Psicologia e Saúde em Debate · doi:10.22289/2446-922x.v10a2a36
The Future of Alcohol Use Disorder Treatment and Research
Srivastava, A. B., & Wai, J. M. (2024) · Psychiatry update · doi:10.1007/978-3-031-73553-0_15
Assisted Psychedelic Psychotherapy: Rethinking the Paradigms of Psychiatric Care?
Mea, E., & Clemente, P. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1008154
Pulido-Saavedra, A., Borelli, A., Kitaneh, R., Alrafayia, M., Khave, L. J., Funaro, M. C., Potenza, M. N., & Angarita, G. A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2446623
“In addition, there are apprehensions toward potential adverse effects, such as psychosis in susceptible populations, with classic and non-classical psychedelics [23– 25].”
Health promotion and premarital education for Adolescents on Instagram @siapnikah_official
Lisnarini, N., Setianti, Y., Gobel, S. A. M., & Safitri, W. F. E. (2024) · COMMICAST · doi:10.12928/commicast.v5i3.12159
A Psilocybin Experience Gone Wrong: The Importance of Psychedelic Assisted Psychotherapy
Forcén, F. E. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2449918
“In this alternative setting, clinicians would attribute the patient’s recovery to the biological effects of psilocybin (Calder and Hasler 2023; Goodwin et al. 2024; Hesselgrave et al. 2021; Mann 2023; Reiff et al. 2020).”
The Birth of Our Free Imagination
Tse, P. U. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198901181.003.0002
Tse, P. U. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198901181.003.0001
Tse, P. U. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198901181.002.0003
Tse, P. U. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198901181.002.0004
The Birth of Good and Evil in Our Free Imaginations
Tse, P. U. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198901181.003.0003
Tse, P. U. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198901181.002.0005
Biological Mechanisms of Stress Resilience: Human and Animal Studies
Seeley, S. H., Boukezzi, S. C., DePierro, J. M., Charney, D. S., & Feder, A. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197640654.003.0041 · Cited by 2
Advances in the diagnosis and treatment of stress-related mental disorders
Zhang, T., Yue, W., Fei, W. A. N. G., Ma, X., Wu, R., Zhao, M., Duan, S., Wang, Y., & Wang, Z. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0348
Cornejo, G. S. E., Cárdenas, F. P., Torres, D., Valderrama, M., & Ettenberger, M. (2025) · Psychoactives · doi:10.3390/psychoactives4020009
Lasch, A., Schweikert, T., Dora, E., Kolb, T., Schurig, H. L., & Walther, A. (2025) · Nervenheilkunde · doi:10.1055/a-2517-1621
Earleywine, M., & Oliva, A. B. (2025) · Psychoactives · doi:10.3390/psychoactives4020014
Educational materials and image induction increase treatment credibility
Low, Z. L. F. (2022) · Scholars Archive - University at Albany (University at Albany, State University of New York) · doi:10.54014/d2ej-5hb3
ALTERNATIVAS FARMACOLÓGICAS PARA O TRATAMENTO DE TRANSTORNOS DE ANSIEDADE: UMA REVISÃO DA LITERATURA
Lopes, R. M. L., Galvão, J. G. F. M., Marques, A. E. F., & Pereira, L. R. D. A. B. (2025) · Revista interdisciplinar em saúde · doi:10.35621/23587490.v12.n1.p1507-1530 · Cited by 1
Investing in Group Psychedelic Therapy for Latinx Immigrants
Zambrano, J., Forcén, F. E., Hidalgo, J., & King, F. (2025) · Journal of Immigrant and Minority Health · doi:10.1007/s10903-025-01702-0
Patel, P. C., & Wolfe, M. T. (2025) · Journal of Business Venturing Insights · doi:10.1016/j.jbvi.2025.e00549
Overall, J. S. (2025) · Applied Psychology Research · doi:10.59400/apr3074
Factors associated with psychedelic attitudes and usage among college students
Hwang, W., Kong, Y., Fujimoto, K., Cen, J., & Villarosa, A. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00427 · Cited by 1
Recent advances in rapid-acting antidepressants
Pan, L., He, Y., Wang, G., & Shen, J. (2025) · Scientia Sinica Chimica · doi:10.1360/ssc-2025-0157
Psychedelic agents for treatment-resistant depression
Gukasyan, N., & Griffiths, R. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00014-1
Psychedelics’ Intoxicating Impact and Behavioural Dynamics
Wasti, A. Z. (2025) · Pharmaceutical science. · doi:10.5772/intechopen.1011743
The therapeutic use of psychedelic drugs: Legal, policy, and neuroscientific perspectives
Rahmani, S., Crupi, R., Riley, A. L., & Davidson, T. L. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.174087 · Cited by 1
Stadler, F., Saelens, J., Henter, I. D., Rieser, N. M., Greenwald, M. S., Ballard, E. D., Preller, K. H., Zarate, C. A., & Kraus, C. (2025) · medRxiv · doi:10.1101/2025.08.27.25334164
Lewandrowski, K.-U., Bowirrat, A., Pinhasov, A., Sharafshah, A., Gold, M. S., Fuehrlein, B., Elman, I., Dennen, C. A., Thanos, P. K., Hanna, C., et al. (2025) · PubMed · Cited by 1
The pharmacology of psychoactive drug abuse and overdose
Thain, A., & Webster, C. A. (2025) · Journal of Paramedic Practice · doi:10.12968/jpar.2025.0071
Calin, A., Burlec, A. F., Mircea, C., Macovei, I., Hăncianu, M., & Corciovă, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186613 · Cited by 3
“This uncertainty reduces access to funding and ultimately investor interest, especially in the EU, where psilocybin is still classified as a controlled substance without exceptions for research in most countries, as is the case in many US states [13].”
InfluentialCharacteristics of Ongoing Clinical Trials of Psychogenic Substances for Psychiatric Disorders
Havlik, J. L., Isaac, S., Raman, P., Tran, N., Hidalgo, K., & Suppes, T. M. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002095
Vlotinou, P., Christodoulou, K., Tsiakiri, A., Christidi, F., & Serdari, A. (2025) · Brazilian Journal of Science · doi:10.14295/bjs.v4i10.785
“…can assist in addressing addictions, palliative care, epilepsy, migraines, cluster headaches, chronic pain, cancer pain, phantom limb syndrome, neurodegenerative disorders, and eating disorders (Ko et al., 2023; Lowe et al., 2021, 2022; Muttoni et al., 2019; Reiff et al., 2020; Schindler, 2022).”
InfluentialJin, S., Wang, H., & Wang, X. (2025) · Psychedelics. · doi:10.61373/pp025v.0038 · Cited by 1
Psychedelics for the Treatment of Substance Use Disorder
Fumàs, B., Pubill, D., López‐Arnau, R., & Nadal‐Gratacós, N. (2025) · Pharmaceutical science. · doi:10.5772/intechopen.1012870 · Cited by 1
Jiang, P., Lin, C., & Wang, X. (2025) · Psychedelics. · doi:10.61373/pp025p.0041
Psychedelics and Mysticism: Mapping Cultural Approaches
Tiaynen-Qadir, T. (2025) · Springer eBooks · doi:10.1007/978-3-031-98596-6_14
Torre, J. T. L., Kam, A., Youngs, T., Rapp, J., & Sackett, N. B. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00467
Psychedelic therapy: a paradigm shift in treating neuropsychiatric disorders
Jin, M., Ji, X., Liu, X., Lu, T., Hashimoto, K., & Lu, L. (2025) · Science China Life Sciences · doi:10.1007/s11427-025-3105-2
Bansal, M., Miller, E., Sumner, R. L., Ponton, R., Muthukumaraswamy, S., & Svirskis, D. M. (2025) · Journal of Chromatographic Science · doi:10.1093/chromsci/bmaf054
Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping ReviewPreprint
Suspène, J., Huet, S., Berteina‐Raboin, S., Benyamina, A., Baril, P., Morisset‐Lopez, S., & Serreau, R. (2025) · Qeios · doi:10.32388/xcfsag
A community-centered approach to psychedelics
Viña, S. M. (2025) · Discover Mental Health · doi:10.1007/s44192-025-00350-y · Cited by 1
“…with treatment-resistant symptoms, preliminary findings suggest these substances may open the door to meaningful short-term relief—typically lasting from several weeks to a few months— before tapering in effect, with results that remain mixed over time (Reiff et al. 2020; Goodwin et al. 2023).”
Chapter 8. Hallucinogens and Phencyclidine
DeVido, J. J., & Epson, M. F. (2025) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894550862.lg08
Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping ReviewPreprint
Suspène, J., Huet, S., Berteina‐Raboin, S., Benyamina, A., Baril, P., Morisset‐Lopez, S., & Serreau, R. (2025) · Qeios · doi:10.32388/xcfsag.2
Gordon, A. R., Carrithers, B. M., Pagni, B. A., Kettner, H., MRes, A. M., Nayak, S. M., Weiss, B., Carhart-Harris, R. L., Roberts, D. E., Erritzøe, D., et al. (2025) · Psychedelic Medicine · doi:10.1177/28314425251382930
Suggested Guidelines for Applying a Systemic Lens to Psychedelic-Assisted Psychotherapy
Lappan, S. N., & Davis, S. D. (2025) · Psychedelic Medicine · doi:10.1177/28314425251404021 · Cited by 3
Ray, K., Rowsey, K., Kramer, L., Kee, M. D., Flores, H., Wise, A., Garrett, M., Rucker, B., Newhardt, R., Beaman, J., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251399554
“…(5-HT2A receptor agonist with β -carboline monoamine oxidase inhibitors) have been studied and re-evaluated for several indications within psychiatry including treatment resistant mood, anxiety, and substance use disorders (Dos Santos et al., 2018; Reiff et al., 2020; Thomas et al., 2017).”
Wongpaiboon, M., Shelton, J. L., Rendon, E. D., & Vail, M. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00373-w · Cited by 2
“Current RCTs that investigated the efficacy of psilocybin on treatment-resistant depression and cancer-related anxiety found significant symptom improvement and sustained effects [89].”
Past-Year Lysergic Acid Diethylamide Use in United States Sexual Minorities from 2015 to 2019
Barnett, B. S., Anand, A., Falcone, T., Altinay, M. I., Dewey, E. N., & Weleff, J. (2025) · Psychedelic Medicine · doi:10.1177/28314425251410086
Contextualizing Violence Risk Associated With Hallucinogens
Durns, T. A., & Iannuzzi, G. (2026) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20250027
Verma, A., Thamilarasan, R., & Kumar, H. (2026) · Future Health · doi:10.25259/fh_74_2025
Montoy, J. C. C., Wang, R. C., Coker, A. R., & Anderson, B. T. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113059
Baseline Mood and “Relational Triad” Predict Acute Qualities of Psychedelic Experience
Lipson, J., Kettner, H., Carhart-Harris, R. L., & Miller, L. (2026) · Behavioral Sciences · doi:10.3390/bs16020310
“…mechanisms, benefits, and potential risks of psychedelics have entered a veritable “renaissance”—with a focus on the potential of psychedelic compounds’ power to treat depression, end-of-life anxiety, addiction, traumatic disorders, and other maladies (Griffiths et al., 2016; Reiff et al., 2020).”
Chemické látky a jejich biologické účinky
Hradil, P., & Soural, M. (2025) · doi:10.5507/prf.25.24466682
Relearning the epistemology, history, and future of neuropsychiatry
Martínez, J. C. C., Rodríguez, F. B., Ramírez‐Bermúdez, J., Bell, V., Lugo, G. F. O., Escudero, J. M. S., Iragorri, A. M., Camprodon, J. A., LAWLOR, B. A., & Santamaría-García, H. (2026) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2026.1727506
Gaughan, S. J., Sevelius, J. M., Lancelotta, R., Anderson, K. D., Davis, A. K., Wootton, A. R., Krantz, D., & James, J. E. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100011
Vyas, R. J., Hood, R., Hsiang, J., Muñoz-Abraham, O., Rueda-Lara, M. A., & Espinel, Z. (2026) · Case Reports in Psychiatry · doi:10.1155/crps/2210511
Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil
Portes, M. A. M., & Bertoglio, L. J. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2644865
Yap, M. M. C., Omer, Y. M. A., Cheng, Y. X., Chan, W. Q., & Ogawa, S. (2026) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2026.100256
Stellmacher, J., Schmidt, C., Aicher, H., Eichel, K., Brakemeier, E., & Herwig, U. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1771726
“Over the past decade, interest in the therapeutic use of psychedelics has seen a resurgence (1 – 3).”
InfluentialHolding space between notes: Music, silence, and cultural attunement in psychedelic-assisted therapy
Balsamo, D. N., Garodia, P., Fayazmanesh, N., & Nguy, A. K. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100015
Metadata
- Authors
- Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R.
- Affiliations
- Emory University (US)
- Department of Psychiatry, New York University School of Medicine, New York (Reiff); Department of Psychiatry and Human Behavior, Emory University School of Medicine, Atlanta (Richman, McDonald); Department of Psychiatry, Dell Medical School and the Institute for Early Life Adversity Research, University of Texas at Austin (Nemeroff); Department of Psychiatry and Human Behavior, Butler Hospital, Brown University, Providence, R.I. (Carpenter); Department of Psychiatry and Behavioral Sciences, University of...
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2020-05-01
- Volume
- 177
- Issue
- 5
- Pages
- 391-410
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W3006905788
- Cited by
- 649
- References
- 120
- Citations by year
- 2026: 93 · 2025: 126 · 2024: 129 · 2023: 113 · 2022: 102 · 2021: 60 · 2020: 26
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG059307)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psychedelics, psychedelic-assisted psychotherapy, psilocybin, LSD, ayahuasca, MDMA, post-traumatic stress disorder, treatment-resistant depression, cancer-related anxiety, substance use disorders, trauma and stress-related disorders, end-of-life care
- MeSH terms
- Mental Disorders, Hallucinogens, Humans, Lysergic Acid Diethylamide, Psilocybin, Psychotherapy, N-Methyl-3,4-methylenedioxyamphetamine, Evidence-Based Practice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.